Display Settings:

Format

Send to:

Choose Destination
    J Clin Pathol. 2007 Mar;60(3):261-6. Epub 2006 Jun 2.

    Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer.

    Source

    Department of Histology and Embryology, Molecular Carcinogenesis Group, School of Medicine, University of Athens, Athens, Greece.

    Abstract

    AIM:

    To study simultaneously the actions of maspin and CXCR4, which share several similar pathways in cancer, including apoptosis and angiogenesis.

    METHODS:

    Our material consisted of 151 invasive breast carcinomas arranged in a tissue microarray setting. Maspin and CXCR4 expression was evaluated by immunohistochemistry. Microvessel density was assessed by CD34 immunodetection and apoptosis by the Tdt-mediated dUTP nick end labelling assay.

    RESULTS:

    Maspin expression was related to CXCR4 expression, apoptosis, patient age and the Nottingham prognostic index. The expression of both maspin and CXCR4 progressively increased in high-grade tumours. In patients with lymph node negative breast cancer, maspin overexpression was associated with increased risk of death. High CXCR4 expression was associated with prolonged survival of patients with high maspin expression.

    CONCLUSIONS:

    Our results show that maspin overexpression could prove to be a potentially useful marker, especially for the clinically important group of patients with lymph node negative breast cancer. The expression of CXCR4 is of less significance in our study, but may be informative for specific patient subsets or in a longer time frame.

    PMID:
    16751302
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC1860569
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Figure 2
    Figure 1

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk